title: Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
authors.forename: Andrea
authors.initials: A
authors.lastname: Mambrini
authors.forename: Claudio
authors.initials: C
authors.lastname: Bassi
authors.forename: Tito
authors.initials: T
authors.lastname: Torri
authors.forename: Massimo
authors.initials: M
authors.lastname: Orlandi
authors.forename: Giammaria
authors.initials: G
authors.lastname: Fiorentini
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cantore
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069287:Capecitabine; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007261:Infusions, Intra-Arterial; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D016019:Survival Analysis; D017211:Treatment Failure; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D015251:Epirubicin; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine